FDA clears Smiths neuraxial medication delivery system

24 September 2012 (Last Updated September 24th, 2012 18:30)

The US Food and Drug Administration (FDA) has granted 510(k) approval to Smiths Medical's neuraxial medication delivery system, designed to minimise the risk of tubing misconnections that occur during spinal and epidural anaesthesia administration.

The US Food and Drug Administration (FDA) has granted 510(k) approval to Smiths Medical's neuraxial medication delivery system, designed to minimise the risk of tubing misconnections that occur during spinal and epidural anaesthesia administration.

The new CorrectInject safety system features safety connectors which deliver spinal and epidural medications to the neuraxial region.

The safety system's yellow components, which visually signify a neuraxial delivery route, help clinicians to check whether the medication to be delivered is appropriate for the treatment location.

The CorrectInject connectors differ from intravenous Luer connectors or intravenous infusion spikes due to the tapered and threaded ends, according to the company.

Smiths Medical president Srini Seshadri said the company is providing a solution that will help clinicians reduce medication delivery errors during spinal and epidural anaesthesia administration.

"As a global leader of safety medical devices, it is our obligation to develop innovative medical products that not only help protect patients when they are most vulnerable but help to raise clinical standards of care," Seshadri said.

UK-based National Patient Safety Agency (NPSA), US-based World Health Organisation and Joint Commission on Accreditation of Healthcare Organisation support the use of new initiatives to reduce the risk of medication administration errors as well as suggest product developers and manufacturers to produce connector systems dedicated for neuraxial applications.

In addition to the US launch, CorrectInject has been available in the UK, Ireland, Australia and parts of Asia since 2011.